Last reviewed · How we verify
Oral estradiol valerate
At a glance
| Generic name | Oral estradiol valerate |
|---|---|
| Sponsor | Universiti Kebangsaan Malaysia Medical Centre |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Acne
- Headache
- Weight increased
- Withdrawal bleeding irregular
- Nasopharyngitis
- Vaginal candidiasis
- Cervical dysplasia
- Nausea
- Metrorrhagia
- Influenza
- Dysmenorrhoea
- Urinary tract infection
Key clinical trials
- Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients (PHASE3)
- Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea (PHASE3)
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PHASE1)
- Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy (NA)
- ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors (PHASE1, PHASE2)
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors (PHASE1)
- Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) (PHASE2)
- Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |